Patients with high-grade endometrial carcinoma (EC) have an increased risk of tumor spread and lymph node metastasis (LNM). Preoperative imaging and CA125 can be used in work-up. As data on cancer antigen 125 (CA125) in high-grade EC are limited, we aimed to study primarily the predictive value of CA125, and secondarily the contributive value of computed tomography (CT) for advanced stage and LNM. Patients with high-grade EC (n = 333) and available preoperative CA125 were included retrospectively. The association of CA125 and CT findings with LNM was analyzed by logistic regression. Elevated CA125 ((>35 U/mL), (35.2% (68/193)) was significantly associated with stage III-IV disease (60.3% (41/68)) compared with normal CA125 (20.8% (26/125), [p < 0.001]), and with reduced disease-specific—(DSS) (p < 0.001) and overall survival (OS) (p < 0.001). The overall accuracy of predicting LNM by CT resulted in an area under the curve (AUC) of 0.623 (p < 0.001) independent of CA125. Stratification by CA125 resulted in an AUC of 0.484 (normal), and 0.660 (elevated). In multivariate analysis elevated CA125, non-endometrioid histology, pathological deep myometrial invasion ≥50%, and cervical involvement were significant predictors of LNM, whereas suspected LNM on CT was not. This shows that elevated CA125 is a relevant independent predictor of advanced stage and outcome specifically in high-grade EC.
ENDORISK is a Bayesian network that can assist in preoperative risk estimation of lymph node metastasis (LNM) risk in endometrial cancer (EC) with consistent performance in external validations. To reflect state of the art care, ENDORISK was optimized by integrating molecular classification and preoperative assessment of myometrial invasion (MI). Variables for POLE, MSI, and preoperative assessment of MI, either by expert transvaginal ultrasound or pelvic magnetic resonance imaging (MRI), were added to develop ENDORISK-2. The p53 biomarker, part of the molecular classification, was already included in ENDORISK. External validation of ENDORISK-2 for LNM prediction was performed in two independent cohorts from: Brno (CZ), (n = 581) and Tübingen (DE), (n = 247). ENDORISK-2 yielded AUCs of 0·85 (95 % CI 0·80-0·90) (CZ) and 0·86 (95 % CI 0·77-0·96) (DE) for predicting LNM. In patients with low-grade histology, 83 % (CZ) and 89 % (DE) were estimated having less than 10 % risk of LNM, with false negative rates (FNR) of 4·3 % (CZ) and 2·2 % (DE). The previously defined set of minimally required variables, i.e.: preoperative tumor grade, three of the four immunohistochemical (IHC) markers, and one clinical marker, could be interchanged with the new variables, with comparable validation metrics, including AUC values of 0·79-0·87 for LNM prediction. Incorporation of molecular data and preoperative MI improved the flexibility of ENDORISK with comparable diagnostic accuracy for estimating LNM as when based on low-cost immunohistochemical biomarkers. In addition, the high diagnostic accuracy in patients with low-grade EC demonstrates how ENDORISK-2 could aid clinicians in identifying patients in whom surgical lymph node assessment may safely be omitted. These results underline its power for clinical use in both high and low resource countries.
Background: The ENDORISK model estimates the risk of lymph node metastases (LNM) in endometrial carcinoma (EC) patients using preoperative clinical variables and biomarkers. This qualitative study investigated healthcare providers' (HCP) perspectives on the use of the model and barriers and facilitators for clinical implementation. Methods: Eight focus group interviews were performed among HCPs. A semi‐structured interview guide was used based on the Grol and Wensing implementation model. Results: Focus groups included gynecologists, residents of gynecology, pathologists, radiation oncologists, and a nurse specialist ( n = 41). ENDORISK was deemed supportive for counseling of patients and shared decision‐making for optimal surgical and adjuvant treatment. Barriers for implementation were difficulty in explaining the model and risk percentages to patients, differences in preoperative diagnostic tools used per hospital, and use of the model with the sentinel node procedure. Facilitators were a clear guideline for using the model with a predefined risk cutoff and making the model easily understandable for patients. A 10% risk cutoff was considered clinically relevant for lymph node assessment. Conclusion: HCP found ENDORISK use in clinical practice supportive for patient counseling. Future implementation should focus on a user‐friendly interface, a cohesive guideline, and training to aid efficient use and counseling of patients.
More than half of endometrial cancer diagnoses can be attributed to obesity. A purely molecular classification in endometrial cancer hampers further understanding of the impact of patient macroenvironment as a major risk factor. The relationship between patient factors, such as age, body mass index (BMI), comorbidity, and ethnicity, and molecular subgroups was studied in a publicly available data set (N = 225) and two multicenter European cohorts (N = 223; N = 946). Age at diagnosis was highest in the TP53-mutated subgroup, and differed significantly between molecular subgroups. Patients with obesity were younger at diagnosis compared to their lean counterparts across all molecular subgroups (61.9 vs. 66.2 years; p < .01). Survival was worst in the TP53-mutated subgroup but improved with increasing BMI, which resulted in nonsignificant differences from other subgroups when BMI was >35. These data underscore that patient factors remain important, and their integration with molecular factors needs to be better understood to ultimately improve treatment and prevention strategies in endometrial cancer.
9 February 2026 in Patient Education and Counseling
A Bayesian network, ENDORISK, estimates a personalized risk of lymph node metastases (LNM) in patients with endometrial cancer (EC). A qualitative study was conducted to assess the perspectives of patients with EC on the use of ENDORISK in preoperative counselling. Content analysis of transcribed semi-structured interviews with 19 patients treated for EC, purposively sampled between 2020 and 2023 from two regional oncology networks in the Netherlands RESULTS: Patients appreciated the potential use of ENDORISK in preoperative counselling to provide information on factors influencing their disease, risk of LNM, and treatment. Use of the model could increase their involvement in decision making on treatment. Emphasizing on the personalized nature of the risk estimation and the potential role of ENDORISK in the decision-making process on treatment could improve explanation of the model. Using ENDORISK in preoperative counselling could potentially increase patient involvement in shared decision making for EC care. A simple explanation of this model is needed and the professional opinion of clinicians remains important in the treatment process. In the development and implementation of clinical risk models it is important to include the perspective of the envisioned patient population to ensure clinical relevancy and explainability. This study provides an explorative groundwork for further investigations in the development and implementation of personalized risk estimation models such as ENDORISK.